Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap

被引：20
作者：
Basu, Sandip [1 ]
Dandekar, Mitali [2 ]
Joshi, Amit [3 ]
D'Cruz, Anil [2 ]
机构：
[1] Tata Mem Hosp, Bhabha Atom Res Ctr, Radiat Med Ctr, Bombay 400012, Maharashtra, India
[2] Tata Mem Hosp, Dept Surg Oncol Head & Neck Serv, Bombay 400012, Maharashtra, India
[3] Tata Mem Hosp, Dept Med Oncol, Bombay 400012, Maharashtra, India
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷 / 08期
关键词：
PHASE-II TRIAL; HISTONE DEACETYLASE INHIBITORS; CANCER CELLS; THERAPY; SORAFENIB; RESVERATROL; EXPERIENCE;
D O I：
10.1007/s00259-015-3058-x
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Nuclear medicine
引用
收藏
页码：1167 / 1171
页数：5
相关论文
共 31 条
  • [1] Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results
    Ain, K. B.
    Lee, C.
    Holbrook, K. M.
    Dziba, J. M.
    Williams, K. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas
    Ain, Kenneth B.
    Lee, Charles
    Williams, Kevin D.
    [J]. THYROID, 2007, 17 (07) : 663 - 670
  • [3] Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
    Brose, Marcia S.
    Nutting, Christopher M.
    Jarzab, Barbara
    Elisei, Rossella
    Siena, Salvatore
    Bastholt, Lars
    de la Fouchardiere, Christelle
    Pacini, Furio
    Paschke, Ralf
    Shong, Young Kee
    Sherman, Steven I.
    Smit, Johannes W. A.
    Chung, John
    Kappeler, Christian
    Pena, Carol
    Molnar, Istvan
    Schlumberger, Martin J.
    [J]. LANCET, 2014, 384 (9940) : 319 - 328
  • [4] Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience
    Cabanillas, Maria E.
    Waguespack, Steven G.
    Bronstein, Yulia
    Williams, Michelle D.
    Feng, Lei
    Hernandez, Mike
    Lopez, Adriana
    Sherman, Steven I.
    Busaidy, Naifa L.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06) : 2588 - 2595
  • [5] Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study
    Cohen, Ezra E. W.
    Rosen, Lee S.
    Vokes, Everett E.
    Kies, Merrill S.
    Forastiere, Arlene A.
    Worden, Francis P.
    Kane, Madeleine A.
    Sherman, Eric
    Kim, Sinil
    Bycott, Paul
    Tortorici, Michael
    Shalinsky, David R.
    Liau, Katherine F.
    Cohen, Roger B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) : 4708 - 4713
  • [6] Sustained clinical responses to tyrosine kinase inhibitor sunitinib thyroid carcinoma
    Dawson, Sarah-Jane
    Conus, Nelly Marmy
    Toner, Guy C.
    Raleigh, Jeanette M.
    Hicks, Rodney J.
    McArthur, Grant
    Rischin, Danny
    [J]. ANTI-CANCER DRUGS, 2008, 19 (05) : 547 - 552
  • [7] CHEMOTHERAPY IN METASTATIC NONANAPLASTIC THYROID-CANCER - EXPERIENCE AT THE INSTITUT-GUSTAVE-ROUSSY
    DROZ, JP
    SCHLUMBERGER, M
    ROUGIER, P
    GHOSN, M
    GARDET, P
    PARMENTIER, C
    [J]. TUMORI, 1990, 76 (05) : 480 - 483
  • [8] Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin
    Furuya, F
    Shimura, H
    Suzuki, H
    Taki, K
    Ohta, K
    Haraguchi, K
    Onaya, T
    Endo, T
    Kobayashi, T
    [J]. ENDOCRINOLOGY, 2004, 145 (06) : 2865 - 2875
  • [9] Grünwald F, 1998, J NUCL MED, V39, P1903
  • [10] Phase II trial of sorafenib in advanced thyroid cancer
    Gupta-Abramson, Vandana
    Troxel, Andrea B.
    Nellore, Anoma
    Puttaswamy, Kanchan
    Redlinger, Maryann
    Ransone, Kathy
    Mandel, Susan J.
    Flaherty, Keith T.
    Loevner, Laurie A.
    O'Dwyer, Peter J.
    Brose, Marcia S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) : 4714 - 4719
1234